Inherited Thrombocytopenia Due to GATA-1 Mutations

ABSTRACT

The GATA family of transcription factors, including the founding member, GATA-1, have an important role in gene regulation. GATA-1 is integral to successful hematopoiesis. A wide variety of mutations in GATA-1 affect its function, as well as its interaction with its cofactors (especially Friend of GATA) and the genes upon which GATA-1 acts. Here we review the known mutations, focusing on the specific alterations within the amino acid sequence, the resulting effect on hematopoietic development, and the clinical manifestations that result. Attention is also paid to the relationship between Trisomy 21, also known as Down syndrome, and the phenomenon of a truncated GATA-1, named GATA-1s. The evidence for specific interaction between GATA-1 and chromosome 21, which may explain the correlation between these two mutations, is briefly reviewed.

KEYWORDS

GATA-1 - Friend of GATA - Trisomy 21 - thrombocytopenia - megakaryocytes

REFERENCES

• 1 Tsai S F, Martin D I, Zon L I, D'Andrea A D, Wong G G, Orkin S H. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells.  Nature. 1989;  339 (6224) 446-451
• 2 Zon L I, Tsai S F, Burgess S, Matsudaira P, Bruns G A, Orkin S H. The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome.  Proc Natl Acad Sci U S A. 1990;  87 (2) 668-672
• 3 Lowry J A, Mackay J P. GATA-1: one protein, many partners.  Int J Biochem Cell Biol. 2006;  38 (1) 6-11
• 4 Pevny L, Simon M C, Robertson E et al.. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1.  Nature. 1991;  349 (6306) 257-260
• 5 Pevny L, Lin C S, D'Agati V, Simon M C, Orkin S H, Costantini F. Development of hematopoietic cells lacking transcription factor GATA-1.  Development. 1995;  121 (1) 163-172
• 6 Fujiwara Y, Browne C P, Cunniff K, Goff S C, Orkin S H. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1.  Proc Natl Acad Sci U S A. 1996;  93 (22) 12355-12358
• 7 Shivdasani R A, Fujiwara Y, McDevitt M A, Orkin S H. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.  EMBO J. 1997;  16 (13) 3965-3973
• 8 Hirasawa R, Shimizu R, Takahashi S et al.. Essential and instructive roles of GATA factors in eosinophil development.  J Exp Med. 2002;  195 (11) 1379-1386
• 9 Migliaccio A R, Rana R A, Sanchez M et al.. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant.  J Exp Med. 2003;  197 (3) 281-296
• 10 Martin D I, Zon L I, Mutter G, Orkin S H. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages.  Nature. 1990;  344 (6265) 444-447
• 11 Wakabayashi J, Yomogida K, Nakajima O et al.. GATA-1 testis activation region is essential for Sertoli cell-specific expression of GATA-1 gene in transgenic mouse.  Genes Cells. 2003;  8 (7) 619-630
• 12 Balduini C L, Pecci A, Loffredo G et al.. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis.  Thromb Haemost. 2004;  91 (1) 129-140
• 13 Tsang A P, Fujiwara Y, Hom D B, Orkin S H. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG.  Genes Dev. 1998;  12 (8) 1176-1188
• 14 Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage.  Acta Haematol. 2002;  108 (4) 237-245
• 15 Cantor A B. GATA transcription factors in hematologic disease.  Int J Hematol. 2005;  81 (5) 378-384
• 16 Vyas P, Ault K, Jackson C W, Orkin S H, Shivdasani R A. Consequences of GATA-1 deficiency in megakaryocytes and platelets.  Blood. 1999;  93 (9) 2867-2875
• 17 Tsang A P, Visvader J E, Turner C A et al.. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation.  Cell. 1997;  90 (1) 109-119
• 18 Chang A N, Cantor A B, Fujiwara Y et al.. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis.  Proc Natl Acad Sci U S A. 2002;  99 (14) 9237-9242
• 19 Zhu Q, Watanabe C, Liu T et al.. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.  Blood. 1997;  90 (7) 2680-2689
• 20 Mehaffey M G, Newton A L, Gandhi M J, Crossley M, Drachman J G. X-linked thrombocytopenia caused by a novel mutation of GATA-1.  Blood. 2001;  98 (9) 2681-2688
• 21 Nichols K E, Crispino J D, Poncz M et al.. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1.  Nat Genet. 2000;  24 (3) 266-270
• 22 Freson K, Devriendt K, Matthijs G et al.. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation.  Blood. 2001;  98 (1) 85-92
• 23 Freson K, Matthijs G, Thys C et al.. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation.  Hum Mol Genet. 2002;  11 (2) 147-152
• 24 Ciovacco W A, Raskind W H, Kacena M A. Human phenotypes associated with GATA-1 mutations.  Gene. 2008;  427 (1-2) 1-6
• 25 Del Vecchio G C, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1.  Acta Haematol. 2005;  114 (2) 113-116
• 26 White J G. Platelet pathology in carriers of the X-linked GATA-1 macrothrombocytopenia.  Platelets. 2007;  18 (8) 620-627
• 27 White J G, Nichols W L, Steensma D P. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry.  Platelets. 2007;  18 (6) 436-450
• 28 Raskind W H, Niakan K K, Wolff J et al.. Mapping of a syndrome of X-linked thrombocytopenia with Thalassemia to band Xp11-12: further evidence of genetic heterogeneity of X-linked thrombocytopenia.  Blood. 2000;  95 (7) 2262-2268
• 29 Hughan S C, Senis Y, Best D et al.. Selective impairment of platelet activation to collagen in the absence of GATA1.  Blood. 2005;  105 (11) 4369-4376
• 30 Tubman V N, Levine J E, Campagna D R et al.. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation.  Blood. 2007;  109 (8) 3297-3299
• 31 Yu C, Niakan K K, Matsushita M, Stamatoyannopoulos G, Orkin S H, Raskind W H. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction.  Blood. 2002;  100 (6) 2040-2045
• 32 Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in gray platelet syndrome.  Tohoku J Exp Med. 1984;  143 (3) 261-287
• 33 Salles I I, Feys H B, Iserbyt B F, De Meyer S F, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function.  Blood Rev. 2008;  22 (3) 155-172
• 34 Clauser S, Cramer-Bordé E. Role of platelet electron microscopy in the diagnosis of platelet disorders.  Semin Thromb Hemost. 2009;  35 (2) 213-223
• 35 Gunay-Aygun M, Zivony-Elboum Y, Gumruk F et al.. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.  Blood. 2010;  116 (23) 4990-5001
• 36 Balduini C L, De Candia E, Savoia A. Why the disorder induced by GATA1 Arg216Gln mutation should be called “X-linked thrombocytopenia with thalassemia” rather than “X-linked gray platelet syndrome”.  Blood. 2007;  110 (7) 2770-2771 author reply 2771
• 37 Phillips J D, Steensma D P, Pulsipher M A, Spangrude G J, Kushner J P. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.  Blood. 2007;  109 (6) 2618-2621
• 38 Bishop D F, Schneider-Yin X, Clavero S, Yoo H W, Minder E I, Desnick R J. Congenital erythropoietic porphyria: a novel uroporphyrinogen III synthase branchpoint mutation reveals underlying wild-type alternatively spliced transcripts.  Blood. 2010;  115 (5) 1062-1069
• 39 Ged C, Moreau-Gaudry F, Richard E, Robert-Richard E, de Verneuil H. Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype.  Cell Mol Biol (Noisy-le-grand). 2009;  55 (1) 53-60
• 40 Hindmarsh J T. The porphyrias: recent advances.  Clin Chem. 1986;  32 (7) 1255-1263
• 41 Hollanda L M, Lima C S, Cunha A F et al.. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis.  Nat Genet. 2006;  38 (7) 807-812
• 42 Wechsler J, Greene M, McDevitt M A et al.. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.  Nat Genet. 2002;  32 (1) 148-152
• 43 Roy A, Roberts I, Norton A, Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.  Br J Haematol. 2009;  147 (1) 3-12
• 44 Tigay J H. A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.  J Pediatr Oncol Nurs. 2009;  26 (6) 362-368
• 45 Ahmed M, Sternberg A, Hall G et al.. Natural history of GATA1 mutations in Down syndrome.  Blood. 2004;  103 (7) 2480-2489
• 46 Crispino J D. GATA1 in normal and malignant hematopoiesis.  Semin Cell Dev Biol. 2005;  16 (1) 137-147
• 47 Crispino J D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.  Pediatr Blood Cancer. 2005;  44 (1) 40-44
• 48 Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.  Leukemia. 2005;  19 (8) 1355-1360
• 49 Waltzer L, Ferjoux G, Bataillé L, Haenlin M. Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis.  EMBO J. 2003;  22 (24) 6516-6525
• 50 Elagib K E, Racke F K, Mogass M, Khetawat R, Delehanty L L, Goldfarb A N. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.  Blood. 2003;  101 (11) 4333-4341